Lipid-Lowering Efficacy and Adverse Events of CETP Inhibitor Combination Therapy: A Systematic Review and Network Meta-Analysis
Our meta-analysis demonstrated that CETP inhibitor combination therapies offer distinct lipid-modulating benefits and safety profiles. The obicetrapib + ezetimibe + statin triple therapy showed superior comprehensive efficacy, while obicetrapib + statin exhibited the optimal safety. Evacetrapib + statin provided potent LDL-C reduction but had the poorest safety. These findings facilitate personalized treatment selection for dyslipidemia management.
Authors
- Xinlin Xiong (ORCID: https://orcid.org/0000-0002-6186-1301)
- Xinlin Yu (ORCID: https://orcid.org/0000-0002-3622-8416)
- Ping Guo (ORCID: https://orcid.org/0000-0003-4901-334X)
- Xu Wei
- Jie Jiang
Institutions
- Sichuan University (CN)
- Affiliated Hospital of Southwest Medical University (CN)
- West China Hospital of Sichuan University (CN)
- Chengdu University (CN)
- Zigong First People's Hospital (CN)
- Second Affiliated Hospital of Chengdu University of Traditional Chinese (CN)
Publication Details
- Journal
- Journal of Cardiovascular Pharmacology
- Published
- 2025-12-24
- DOI
- https://doi.org/10.1097/fjc.0000000000001785
- Primary Topic
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Type
- article
- Field-Weighted Citation Impact
- 0.00